The US Centers for Medicare & Medicaid Services (CMS) has approved the removal of offset charges associated with pass-through payment for drug-coated balloons (DCBs) under Medicare outpatient prospective payment system.
Edixomed presented its interim data from the ProNOx 1 study at the 7th International Symposium on the Diabetic Foot (20–23 May, The Hague, the Netherlands).
The World Conference on Interventional Oncology (WCIO) is developing an online interventional oncology curriculum called IO University. Michael Soulen, immediate past chair of the WCIO, told Interventional News: “One of the gaps in interventional radiology training is in oncology education. If you do an interventional radiology fellowship, you receive very little education in oncology; you learn how to do procedures, but you do not learn about cancer or what the other specialists do. You do not learn to be an effective participant in the oncology scene. The IO University is designed to address these gaps.”
Biotronik has announced the publication of promising clinical results regarding its Pulsar-18 stent platform. Adding to the data collected in the earlier 4EVER1 and PEACE2 trials, the new results published in Clinical Medical Insights: Cardiology further confirm the safety and efficacy of the Pulsar-18 self-expanding nitinol stent, with positive patency results for very challenging cases of femoropopliteal disease.
Non-thermal, non-tumescent technologies to treat varicose veins were shown to have comparable short-term outcomes to those obtained with thermal technologies at the recent Charing Cross Symposium (28 April–1 May, London, UK).
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of Eliquis (apixaban) as an option for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults.
Baxter International has announced it is voluntarily recalling four product codes of its Vascu-Guard Peripheral Vascular Patch.
A new line of medical devices has the potential to save the lives of millions of haemodialysis patients and billions of dollars’ worth of secondary medical treatments, NuVascular Technologies has announced. The suite of products uses NuVascular’s patented nanotechnology to develop devices such as access grafts and sutures that can be loaded with specific drugs to treat patients afflicted with kidney disease by delivering the drug directly to a precise site for a defined period of time while significantly reducing the risks associated with these types of devices.
Cardinal Health announced on 28 May 2015 that its 1 March 2015 binding offer to acquire Johnson & Johnson’s Cordis business for US$1.944 billion in cash was formally accepted.
Bristol-Myers Squibb and Pfizer have announced that the National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of Eliquis (apixaban) as an option for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. As part of the 90-day implementation plan, the National Health Service (NHS) now has three months for apixaban to be made available to patients in England and Wales whose doctors believe it is a clinically appropriate treatment for them.
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--Cardiovascular Systems, Inc. (CSII) (CSI), announced today that it has received FDA clearance for the new 4 French (4 Fr) 1.25 Solid Diamondback 360® Peripheral Orbital Atherectomy System (OAS) for the treatment of peripheral artery disease (PAD).
LOWELL, Mass.--(Healthcare Sales & Marketing Network)--Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions, announced that the Alcyone MEMS Cannula (AMC™), a neuro-ventricular cannula, has received FDA clearance. The AMC is a dual-lumen, MRI-compatible injection and aspiration cannula for use in the brain. The AMC is not intended for implant, and it is intended for single patient use only.
BALTIMORE, April 23, 2015 -- (Healthcare Sales & Marketing Network) -- Clear Guide Medical announces that its first clinical product, the Clear Guide ONE, has received the CE Mark from its Notified Body. The CE Mark allows the marketing and sale of the medical device in 28 Member States of the European Union, as well as Iceland, Norway, Liechtenstein, Switzerland and Turkey.
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the publication of the first clinical experience with supporting preclinical data in the Journal of the American College of Cardiology: Cardiovascular Interventions.
TEWKSBURY, Mass.--(Healthcare Sales & Marketing Network)--Mitralign today highlighted a presentation by Prof. Dr. med. J. Schofer of the Medicare Center and Department for Percutaneous Interventions of Structural Heart Disease, Albertinen Heart Center, Hamburg at the recent American College of Cardiology (ACC) Scientific Sessions detailing his experience with the Mitralign Transcatheter Annuloplasty System. At ACC, Schofer discussed his successful use of the Mitralign System to perform a direct transcatheter annuloplasty on special access patients with tricuspid regurgitation (TR). The Mitralign system is not approved for sale or distribution however, it is currently being evaluated in clinical trials for an indication in functional mitral regurgitation.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos